Invitation | Shenzhen, February 29: Join EClinCloud to Discuss Accelerating Clinical Drug Research and Improving R&D Success Rates

Source: EClinCloud. Author: EClinCloud.
Guiding Organizations: Chinese Society of Biotechnology, Shenzhen Pingshan District Science and Technology Innovation Bureau
Organizers: R&G PharmaStudies, EClinCloud, Shenzhen Biomedicine Innovations Industrial Park, Shenzhen Pingshan District Biomedical Industry Innovation Chain Party Committee, Huoshi Shulian
Date and Time: Thursday, February 29, 2024, 13:30-17:00
Venue: Lecture Hall, Floor 4, Building 4, Shenzhen Biomedicine Innovations Industrial Park, No. 14 Jinhui Road, Pingshan District, Shenzhen


13:30-13:40
Leadership Remarks
13:40-14:10
Model-Informed Drug Development
Hu Bei Chief Clinical Pharmacologist, R&G PharmaStudies; Founder, Lingchu Pharma
14:10-14:40
Begin with the End in Mind: Interpreting Regulatory Review Flexibility from a Clinical Value Perspective
Li Jigang Chief Medical Officer, R&G PharmaStudies
14:40-15:10
Begin with the End in Mind: Enabling More Accurate Clinical Outcome Assessment (COA) Through Digitalization and Intelligence
Qin Long, Founder & CEO, EClinCloud
15:10-15:40
Introduction to New Drug Registration in the EU and Key Considerations
Qiu Jiancheng Vice President and Head of Regulatory Affairs (RA), R&G PharmaStudies
15:40-16:10
Early Prediction of Human PK and Dose Based on ADME Characteristics of Innovative Drugs
Gao Zhiwei General Manager, Shanghai Hengling Pharmaceutical Technology Co., Ltd.
16:10-16:50
Panel Discussion: How to Accelerate Clinical Drug Research and Improve Drug R&D Success Rates?
Moderator: Li Jigang, Chief Medical Officer, R&G PharmaStudies
Panelists:
Chen Gang, Chief Scientific Officer, R&G PharmaStudies
Hu Bei, Chief Clinical Pharmacologist, R&G PharmaStudies
Qiu Jiancheng, Vice President, R&G PharmaStudies
Qin Long, Founder & CEO, EClinCloud
Gao Zhiwei, General Manager, Shanghai Hengling Pharmaceutical Technology Co., Ltd.
16:50-17:00
Q&A

Chen Gang
Chief Scientific Officer, R&G PharmaStudies
- Ph.D. in Statistics, University of Maryland, USA, with 30+ years of biostatistics experience at the U.S. FDA and in the pharmaceutical industry;
- Previously served as Senior Statistical Reviewer and Division Director in the biostatistics division of the U.S. FDA's oncology drug review center, and as Head of Clinical Biostatistics for Oncology Drug R&D at Johnson & Johnson (U.S.) and Head of Quantitative Sciences at Johnson & Johnson (China);
- Founder of Aikeman Information Technology Co., Ltd., a subsidiary of R&G PharmaStudies.

Hu Bei
M.D., Peking Union Medical College; Postdoctoral Fellow, Department of Medicinal Chemistry, University of Washington, USA; formerly Doctoral Advisor and Professor of Clinical Pharmacology at Peking Union Medical College Hospital;
30+ years of experience in clinical pharmacology teaching, practice, and clinical research on innovative drugs, having participated in 100+ Phase I/II clinical trials of innovative drugs and published 130+ SCI articles;
Currently Chief Clinical Pharmacologist at R&G PharmaStudies and Founder of its subsidiary Lingchu Pharmaceutical Technology Co., Ltd.

Li Jigang
Chief Medical Officer, R&G PharmaStudies
- Master's degree in Pathology, University of Rochester (USA);
- 16 years of experience in clinical R&D and medical affairs at Johnson & Johnson and R&G PharmaStudies;
- Led R&D strategies for 50+ innovative drugs across multiple therapeutic areas, including CNS, hematology, oncology, immunology, cardiovascular, and endocrinology.

Qin Long
Founder and CEO, EClinCloud
Ph.D. in Management, Beihang University; postdoctoral research in medical statistics, Sun Yat-sen University.
Over 17 years of experience in the clinical research industry, and a pioneer in China in applying new IT technologies to improve the quality and efficiency of clinical trials;
An innovative and inspiring leader, and a pioneer in promoting and implementing technology solutions such as eCOA, EDC, and CTMS in China's clinical research field;
Previously served as Asia-Pacific head of an international technology company, leading rapid business growth across the region;
An entrepreneur driven by academia and science, dedicated with great passion to shaping future clinical trial models.

Qiu Jiancheng
Vice President and Head of Regulatory Affairs (RA), R&G PharmaStudies
- Master's degree in Pharmaceutics, Academy of Military Medical Sciences; 18 years of experience in drug and medical device registration and regulatory affairs;
- Previously held positions at well-known pharmaceutical companies including Novartis, Sanofi (Genzyme), and Clinipace, serving as (Senior) Regulatory Affairs Manager, Regulatory Affairs Director, and Head of Asia-Pacific Regional Regulatory Affairs.

Gao Zhiwei
General Manager, Shanghai Hengling Pharmaceutical Technology
- Ph.D. in Clinical Pharmacology, Fudan University; Youth Committee Member of the Drug Metabolism Professional Committee, Chinese Pharmacological Society.
- Co-founded Shanghai Hengling Pharmaceutical Technology Co., Ltd. in October 2019;
- 2006–2019: Research on pharmacokinetics and drug metabolism of innovative drugs, Shanghai Institute of Materia Medica, Chinese Academy of Sciences;
- 17 years of experience in ADME research on innovative drugs and specialty formulations, having participated in completing ADME evaluations for 280+ innovative drugs, with over 200 approved to enter clinical trials and 10 new drugs approved for marketing;
- Specializes in PK data analysis and PBPK modeling, and has published 18 SCI papers;
- Contributing author to the monograph "Research on Metabolism and Pharmacokinetics of Innovative Drugs".
In 2024, the R&G PharmaStudies Park Tour sets off again with a full upgrade, partnering for its first stop with Shenzhen Biomedical Innovation Industrial Park, EClinCloud, and Huoshi Shulian to head to Shenzhen.
For any pharmaceutical company, advancing a drug candidate into Phase I clinical trials after rigorous optimization in the preclinical stage is a major achievement. However, once in clinical research, nine out of ten drug candidates fail during Phase I, II, and III clinical trials and the drug approval process. It is also worth noting that this 90% failure rate applies to drug candidates that have already entered Phase I clinical trials and does not include those still in the preclinical stage.
We sincerely welcome your attendance and look forward to sharing the highlights of the event with you on site!
EClinCloud is a technology company focused on clinical R&D. It provides an integrated, interoperable, all-in-one clinical trial cloud platform (including solutions across technology products and offerings such as eCOA, CTMS, eTMF, EDC, RTSM, and RM, covering scale design, scale copyright management, linguistic validation, rater training, and data quality analysis, among others) as well as clinical trial endpoint assessment technologies across therapeutic areas (including central nervous system and ophthalmology, among others). By combining cutting-edge technology with life data, it is building a globally leading, patient-centric SaaS cloud platform for clinical evidence support to help domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the market launch of drugs and devices, and benefit countless patients.



